Skip to main content

Table 3 Clinical outcomes of all patients with and without diabetes, and of all patients with and without diabetes stratified according to medical therapy or successful CTO-PCI

From: Long-term outcomes of medical therapy versus successful recanalisation for coronary chronic total occlusions in patients with and without type 2 diabetes mellitus

Total population

Non-diabetes

Diabetes

P value

(n = 1260)

(n = 755)

Cardiac death

59 (4.7)

38 (5.0)

 

Adjusted HR (95% CI)

1

1.13 (0.73–1.75)

0.597

MI

86 (6.8)

69 (9.1)

 

Adjusted HR (95% CI)

1

1.38 (0.98–1.92)

0.058

TVR

155 (12.3)

113 (15.0)

 

Adjusted HR (95% CI)

1

1.41 (1.10–1.81)

0.006

MACE

257 (20.4)

192 (25.4)

 

Adjusted HR (95% CI)

1

1.32 (1.09–1.61)

0.005

Patients with diabetes

Medical therapy

Successful PCI

P value

(n = 506)

(n = 249)

Cardiac death

33 (6.5)

5 (2.0)

 

Adjusted HR (95% CI)

1

0.29 (0.10–0.80)

0.017

MI

50 (9.9)

19 (7.6)

 

Adjusted HR (95% CI)

1

0.75 (0.44–1.30)

0.305

TVR

79 (15.6)

34 (13.7)

 

Adjusted HR (95% CI)

1

0.76 (0.50–1.17)

0.212

MACE

146 (28.9)

46 (18.5)

 

Adjusted HR (95% CI)

1

0.61 (0.42–0.87)

0.006

Patients with diabetes

Medical therapy

Successful PCI

P value

(n = 791)

(n = 469)

Cardiac death

41 (5.2)

18 (3.8)

 

Adjusted HR (95% CI)

1

0.94 (0.51–1.70)

0.825

MI

56 (7.1)

30 (6.4)

 

Adjusted HR (95% CI)

1

1.01 (0.62–1.65)

0.959

TVR

109 (13.8)

46 (9.8)

 

Adjusted HR (95% CI)

1

0.85 (0.59–1.22)

0.389

MACE

180 (22.8)

77 (16.4)

 

Adjusted HR (95% CI)

1

0.85 (0.64–1.15)

0.294

  1. Values are presented as n (%)
  2. CI confidence interval(s), HR hazard ratio, MACE major adverse cardiovascular events, MI myocardial infarction, PCI percutaneous coronary intervention, TVR target-vessel revascularization